-- 据香港交易所周三发布的公告显示，莱克纳制药（港交所代码：2105）称，其口服药物LAE002在一项3期临床试验中达到了主要终点——无进展生存期。 FFIRM-205研究结果显示，LAE002联合氟维司群治疗乳腺癌患者的无进展生存期为7.6个月，而单用氟维司群治疗患者的无进展生存期仅为2个月。 莱克纳制药已与齐鲁制药就LAE002在中国的授权许可达成协议，根据该协议，莱克纳制药有权获得总额高达20.5亿元人民币的首付款和里程碑付款。 莱克纳制药表示，将在“近期”向中国提交LAE002的新药申请。
Related Articles
Asia
Origin Energy Reports Lower March Quarter Production
Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.
$ASX:ORG
Asia
New Hope Says JPMorgan Chase Ceases to be a Substantial Shareholder
New Hope (ASX:NHC) received notice that JPMorgan Chase and its affiliates are no longer substantial holders of the company from April 22, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates became a substantial holder of the company on April 15, with a total voting power of 5.88%, an earlier filing showed.
$ASX:NHC
Asia
Zip Says JPMorgan Chase Increases Stake
Zip (ASX:ZIP) received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 7.42% from 6.27%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now own 93.2 million shares in the company, the filing said.
$ASX:ZIP